[go: up one dir, main page]

CY1119800T1 - Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων - Google Patents

Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων

Info

Publication number
CY1119800T1
CY1119800T1 CY20181100069T CY181100069T CY1119800T1 CY 1119800 T1 CY1119800 T1 CY 1119800T1 CY 20181100069 T CY20181100069 T CY 20181100069T CY 181100069 T CY181100069 T CY 181100069T CY 1119800 T1 CY1119800 T1 CY 1119800T1
Authority
CY
Cyprus
Prior art keywords
inhibitors
acthylcholinesteration
concentrators
connectors
cognitive disorder
Prior art date
Application number
CY20181100069T
Other languages
English (en)
Inventor
David Beattie
Fei Shen
Jacqueline A. M. Smith
Robert Murray Mckinnell
Ray Chang
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of CY1119800T1 publication Critical patent/CY1119800T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση σχετίζεται με τη χρήση ειδικών ενώσεων αγωνιστών του υποδοχέα της 5-ΗΤ4 για τη θεραπεία γνωστικών διαταραχών, συγκεκριμένα με τη χρήση αυτών των ενώσεων σε συνδυασμό με άλλους παράγοντες, ειδικά αναστολείς ακετυλοχολινεστεράσης, για τη θεραπεία της νόσου του Alzheimer και άλλων γνωστικών διαταραχών.
CY20181100069T 2009-04-13 2018-01-19 Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων CY1119800T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16874109P 2009-04-13 2009-04-13
US29255910P 2010-01-06 2010-01-06
PCT/US2010/030760 WO2010120695A2 (en) 2009-04-13 2010-04-12 5-ht4 receptor agonist compounds for treatment of cognitive disorders

Publications (1)

Publication Number Publication Date
CY1119800T1 true CY1119800T1 (el) 2018-06-27

Family

ID=42237213

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100069T CY1119800T1 (el) 2009-04-13 2018-01-19 Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων

Country Status (24)

Country Link
US (2) US8404711B2 (el)
EP (1) EP2419104B1 (el)
JP (1) JP2012523437A (el)
KR (1) KR20120017421A (el)
CN (2) CN105832735A (el)
AU (1) AU2010236734B2 (el)
BR (1) BRPI1013777A8 (el)
CA (1) CA2758321A1 (el)
CY (1) CY1119800T1 (el)
DK (1) DK2419104T3 (el)
ES (1) ES2654930T3 (el)
HR (1) HRP20180018T1 (el)
HU (1) HUE038141T2 (el)
IL (1) IL215660A0 (el)
LT (1) LT2419104T (el)
MX (1) MX2011010782A (el)
NO (1) NO2419104T3 (el)
PL (1) PL2419104T3 (el)
PT (1) PT2419104T (el)
RU (1) RU2569056C2 (el)
SI (1) SI2419104T1 (el)
SM (1) SMT201800036T1 (el)
WO (1) WO2010120695A2 (el)
ZA (1) ZA201107490B (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
NZ613291A (en) 2008-11-19 2014-11-28 Forum Pharmaceuticals Inc Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
RU2011150248A (ru) * 2009-05-11 2013-06-20 Энвиво Фармасьютикалз, Инк. Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы
SG185594A1 (en) 2010-05-17 2012-12-28 Envivo Pharmaceuticals Inc A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
US10874701B2 (en) 2012-08-16 2020-12-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
WO2014027864A1 (ko) 2012-08-16 2014-02-20 경희대학교 산학협력단 노화 및 치매의 예방 및/또는 치료 활성을 갖는 유산균
IL270343B1 (en) 2017-05-24 2025-01-01 H Lundbeck As Combination of a 5-HT6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of Alzheimer's disease in a subpopulation of patients carrying APOE4 alleles
EP3630113A4 (en) 2017-06-01 2021-02-24 Eisai R&D Management Co., Ltd. PHARMACEUTICAL COMPOSITION INCLUDING A PDE9 INHIBITOR
CA3067453C (en) 2017-06-02 2021-11-23 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating brain atrophy
SG11201912266QA (en) 2017-07-31 2020-01-30 Theravance Biopharma R&D Ip Llc Methods of treating symptoms of gastroparesis using velusetrag

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1311272B1 (en) * 2000-03-03 2006-11-22 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7598265B2 (en) 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
MY147756A (en) 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Also Published As

Publication number Publication date
CA2758321A1 (en) 2010-10-21
IL215660A0 (en) 2012-01-31
RU2011146032A (ru) 2013-05-20
US20140057939A1 (en) 2014-02-27
US8404711B2 (en) 2013-03-26
MX2011010782A (es) 2012-01-20
WO2010120695A2 (en) 2010-10-21
SMT201800036T1 (it) 2018-03-08
HUE038141T2 (hu) 2018-10-29
CN102395371A (zh) 2012-03-28
ES2654930T3 (es) 2018-02-15
BRPI1013777A2 (pt) 2016-04-05
US20100261752A1 (en) 2010-10-14
PT2419104T (pt) 2018-01-31
KR20120017421A (ko) 2012-02-28
LT2419104T (lt) 2018-02-12
SI2419104T1 (en) 2018-03-30
AU2010236734B2 (en) 2015-06-11
AU2010236734A1 (en) 2011-11-03
CN105832735A (zh) 2016-08-10
BRPI1013777A8 (pt) 2017-09-19
JP2012523437A (ja) 2012-10-04
AU2010236734A8 (en) 2012-02-16
PL2419104T3 (pl) 2018-04-30
RU2569056C2 (ru) 2015-11-20
WO2010120695A3 (en) 2010-12-02
EP2419104B1 (en) 2017-11-08
EP2419104A2 (en) 2012-02-22
HRP20180018T1 (hr) 2018-02-09
ZA201107490B (en) 2012-06-27
DK2419104T3 (en) 2018-02-05
NO2419104T3 (el) 2018-04-07

Similar Documents

Publication Publication Date Title
CY1119800T1 (el) Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1119057T1 (el) Συνδετες υποδοχεα οπιοειδους και μεθοδοι χρησης και κατασκευης αυτων
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1121065T1 (el) Αναστολεις ιβατ για την αγωγη ηπατικων νοσων
CY1123051T1 (el) Ταπενταδολη για προληψη και θεραπεια καταθλιψης και αγχους
EA201101009A1 (ru) АНТАГОНИСТЫ C5aR
MA32547B1 (fr) Antagonistes specifiques du recepteur fgf-r4
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
CY1114872T1 (el) Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
CY1113980T1 (el) Νεες θεραπευτικες μεθοδευσεις για θεραπευτικη αγωγη cmt και συναφων διαταραχων
ME01532B (me) Jedinjenja
EA201171367A1 (ru) Винилиндазолильные соединения
CY1115975T1 (el) Ταπενταδολη για τη θεραπεια πονου σε αρθριτιδα
EA201170227A1 (ru) Имидазолкарбоксамиды
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
CY1115437T1 (el) Υδροξυμεθυλοκυκλοεξυλαμινες
EA201071248A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
EA201171063A1 (ru) Фармацевтические составы олмесартана
HUE050319T2 (hu) Kompozíciók és eljárások alkoholfogyasztással kapcsolatos rendellenességek, fájdalom és más betegségek kezelésére
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
CY1116802T1 (el) Ετεροκυκλικες ενωσεις
CY1118710T1 (el) Συνθεσεις για την θεραπεια της πολλαπλης σκληρυνσης